Worth reading
56In focus
Scored from 2 of 5 sectionsDirection
Deterioration
Direction inferred from the company’s description.Scale
-5635
¥ millionWording
Avoiding a definitive answer
How definitive the wording is.Revised forecast
Fiscal year ending January 2027 · Cumulative second quarter and full yearOperating profit—→-5,625million
—
Ordinary income—→-5,632million
—
Profit attributable to owners of the parent—→-5,635million
—
Net income per share—→-72.21yen
—
The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Reason for the revision
アクーゴ®の初出荷に関連する費用及び国内での普及に向けた製造・流通・販売体制構築に向けた費用を主に、合計5,625百万円の事業費用を見込む。薬価が未定のため、アクーゴ®に関する事業収益を業績予想に織り込むことを控えている。
Previous-period results営業利益：△3,794百万円、経常利益：△4,291百万円、親会社株主に帰属する当期純利益：△3,842百万円、１株当たり当期純利益：△52.55円（2026年１月期）
Dividend forecast revision2027年１月期の年間配当予想は0.00円。予想修正の有無はNot disclosed。
Consolidated / non-consolidatedConsolidated
| Item | Details |
|---|---|
| Operating profit | Not disclosed → ¥-5,625 million |
| Ordinary income | Not disclosed → ¥-5,632 million |
| Profit attributable to owners of the parent | Not disclosed → ¥-5,635 million |
| Net income per share | Not disclosed → -72.21 yen |
| Fiscal Period Covered | Fiscal year ending January 2027 |
| Period Covered | Cumulative second quarter and full year |
| Previous-period results | 営業利益：△3,794百万円、経常利益：△4,291百万円、親会社株主に帰属する当期純利益：△3,842百万円、１株当たり当期純利益：△52.55円（2026年１月期） |
| Reason for the revision | アクーゴ®の初出荷に関連する費用及び国内での普及に向けた製造・流通・販売体制構築に向けた費用を主に、合計5,625百万円の事業費用を見込む。薬価が未定のため、アクーゴ®に関する事業収益を業績予想に織り込むことを控えている。 |
| Dividend forecast revision | 2027年１月期の年間配当予想は0.00円。予想修正の有無はNot disclosed。 |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (3)
Net SalesPublication date of previous forecastDetails and amount of extraordinary loss
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.アクーゴ®の初出荷に関連する費用と、国内での普及に向けた製造・流通・販売体制の構築費用を主に、合計5,625百万円の事業費用を見込むため。アクーゴ®の薬価が未定であるため、関連する事業収益は業績予想に織り込んでいない。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.